Breaks Categories: News

TuesdaySep 30, 2025 9:20 am

NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board to Advance HyBryte Phase 3 Study 

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases, announced the expansion of its European Medical Advisory Board to guide its confirmatory Phase 3 trial of HyBryte(TM) in early-stage cutaneous T-cell lymphoma, an 18-week study enrolling about 80 patients with top-line results expected in the second half of 2026, as the company strengthens European engagement ahead of potential commercialization. To view the full press release, visit https://nnw.fm/ivOYn About Soligenix Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business…

Continue Reading

TuesdaySep 30, 2025 9:15 am

NetworkNewsBreaks – LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Featured in NetworkNewsAudio Release on Record Gold Prices Driving Near-Term Production Opportunities

LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) is featured in a NetworkNewsAudio Audio Press Release titled “Record Gold Prices Create Unprecedented Opportunities for Near-Term Producers.” The company’s flagship Swanson Gold Project in Quebec, near Abitibi’s prolific gold operations, hosts a current mineral resource estimate of 123.4 Koz Au Indicated and 64.5 Koz Au Inferred, with potential to expand beyond one million ounces. Spanning more than 18,300 hectares with a mining lease and 445 claims, the project benefits from multiple gold-bearing regional structures, district-scale consolidation, and proximity to the Beacon Gold Mill, positioning LaFleur to fast-track production. To view the…

Continue Reading

TuesdaySep 30, 2025 9:00 am

NetworkNewsBreaks – Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Reports Q3 2025 Results and Provides Project Update

Trilogy Metals (NYSE American: TMQ) (TSX: TMQ) reported a net loss of $1.7 million for the three months ended Aug. 31, 2025, compared to a net loss of $1.6 million in the same period last year. The higher loss was primarily driven by environmental baseline work and the start of a core re-boxing program conducted by Ambler Metals LLC, the Company’s 50/50 joint venture with South32 Ltd. (ASX, LSE, JSE: S32; ADR: SOUHY). For the nine months ended Aug. 31, 2025, Trilogy reported a net loss of $7.5 million versus $7.0 million in 2024, reflecting increased regulatory and legal expenses…

Continue Reading

TuesdaySep 30, 2025 9:00 am

NetworkNewsBreaks – Branded Legacy, Inc. (OTC: BLEG) Subsidiary Files Provisional Patent for Intranasal Drug Delivery Platform

Branded Legacy (OTC: BLEG), a holding company focused on innovative life sciences and wellness solutions, announced that its subsidiary BioLegacy Evaluative Group Inc. has filed a provisional patent application with the U.S. Patent and Trademark Office for its “Air-Driven Unitary Intranasal Drug Delivery Device for Stable and Reconstitutable Medicaments,” a compact, air-powered platform designed to provide precise, reliable, and cost-effective intranasal dosing for both stable formulations such as naloxone and unstable drugs requiring on-demand reconstitution. To view the full press release, visit https://nnw.fm/xiEWz About Branded Legacy, Inc. Branded Legacy, Inc. (OTC: BLEG) is a forward-thinking holdings company dedicated to pioneering solutions in…

Continue Reading

MondaySep 29, 2025 12:06 pm

NetworkNewsBreaks – InvestorWire Taps IgnitionX to Supercharge Release Reach 

IBN (InvestorBrandNetwork) dynamic brand InvestorWire, already known for delivering wire-grade press release distribution through IBN’s network,  is now integrating its reach with IgnitionX, IBN’s programmatic ad platform, to drive precision investor targeting. Using IgnitionX, companies can take a news release beyond the wire, placing the message directly in front of the right investors across Google, Meta, LinkedIn, TikTok, YouTube, Reddit and more. This hybrid model means a single press release isn’t just syndicated broadly, it’s amplified intelligently: the release gets the traditional InvestorWire push and then is actively retargeted through IgnitionX to those investor audiences most likely to engage. The…

Continue Reading

MondaySep 29, 2025 11:34 am

NetworkNewsBreaks – VolitionRx (NYSE American: VNRX) Signs Co-Marketing and Services Agreement with Hologic (NASDAQ: HOLX) 

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it has entered into a co-marketing and services agreement with Hologic Diagenode, part of Hologic Inc. (NASDAQ: HOLX), to promote Volition’s Nu.Q® Discover service. The program offers drug developers and scientists a suite of assays for rapid epigenetic profiling across disease model development, preclinical testing, and clinical studies. “This is a significant milestone for our Nu.Q® Discover program and will greatly expand customer access to our proprietary Nu.Q® Discover assays, which have an estimated total addressable market of $200 million annually,” said Dr. Jasmine Kway, Chief Executive Officer…

Continue Reading

MondaySep 29, 2025 11:12 am

NetworkNewsBreaks – LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Featured in NetworkNewsWire Editorial on Soaring Gold Prices and Emerging Producers 

LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) announced its inclusion in a NetworkNewsWire editorial titled “Soaring Gold Prices Open Doors for Emerging Producers.” With gold trading above $3,500 an ounce amid inflation concerns, currency pressures, and slowing global growth, companies nearing production stand to benefit significantly. Positioned for near-term production, LaFleur owns a fully permitted, modernized gold mill and strategically located projects in one of Canada’s most productive mining regions, offering a timely value proposition for investors. To view the full press release, visit https://nnw.fm/caEsK About LaFleur Minerals Inc. LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) is…

Continue Reading

MondaySep 29, 2025 10:57 am

NetworkNewsBreaks – FAVO Capital (OTC: FAVO) Appoints Dr. Wael Barsoum as Independent Director 

FAVO Capital (OTC: FAVO), a diversified financial company with operations in financial services and real estate, announced the appointment of Dr. Wael Barsoum to its board of directors as an independent director. Barsoum, former president and CEO of Cleveland Clinic Florida and current president and chief transformation officer at Healthcare Outcomes Performance Company, brings decades of leadership in healthcare innovation, governance, and organizational growth. “Wael’s appointment reflects our commitment to building a board with the independence, depth, and experience to guide FAVO’s next chapter,” said Shaun Quin, president of FAVO Capital. To view the full press release, visit https://nnw.fm/gLEvl About FAVO Capital,…

Continue Reading

MondaySep 29, 2025 10:20 am

NetworkNewsBreaks – Nicola Mining Inc. (TSXV: NIM) (FSE: HLIA) (OTCQB: HUSIF) Expands Gravel Pit Operations and Completes Cement Ready Mix Plant

Nicola Mining (TSXV: NIM) (FSE: HLIA) (OTCQB: HUSIF) together with partner Lower Nicola Site Services Ltd., announced the long-term expansion of its wholly owned gravel pit (Permit G1519) and completion of construction of its cement ready mix plant. The company has secured two significant permits: a Notice of Departure at the New Craigmont Project allowing extraction of up to 3.0 million tonnes of inert rock material at approximately 1,500 tonnes per day, and an extension of its gravel pit mine life alongside a provincial highway permit received Sept. 5, 2025. To view the full press release, visit https://nnw.fm/9XHH5 About Nicola Mining…

Continue Reading

MondaySep 29, 2025 10:10 am

NetworkNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Re-files ANDA for Preservative-Free IV Ketamine KETAFREE(TM)

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has re-filed its Abbreviated New Drug Application with the U.S. FDA for KETAFREE(TM), a preservative-free IV ketamine formulation, covering all existing approved indications, following FDA approval of its Suitability Petition. Targeting a ketamine market estimated at $750 million annually in the U.S. and projected to reach $3.35 billion globally by 2034, NRx is seeking priority review amid an ongoing drug shortage, citing its patented formulation manufactured with Nephron Pharmaceuticals in South Carolina as a safer alternative free of benzethonium chloride, a preservative linked to neurotoxicity. To view the full press release, visit https://ibn.fm/O5lcF About…

Continue Reading